Physician profile
Scott Blattman
NPI 1023082146
$2,236.41
in general payments reported to CMS, 2019-2025
31 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $102 · 2021: $75.58 · 2022: $155 · 2023: $220 · 2024: $663 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $273.62 | 2022-2024 | Farxiga, Breztri |
| Dexcom, INC. | $205.77 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $187.78 | 2019 | |
| Glaxosmithkline, LLC. | $174.96 | 2019-2023 | Arexvy |
| Pfizer INC. | $151.76 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $112.33 | 2024 | Voquezna |
| Abbvie INC. | $53.24 | 2019-2022 | |
| Intuitive Surgical, INC. | $50.00 | 2023 | Da Vinci Surgical System |
| Sanofi-Aventis U.S. LLC | $39.86 | 2023-2025 | |
| Allergan, INC. | $37.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.52 | 2024 | Rexulti |
| Lilly USA, LLC | $34.13 | 2019-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $29.64 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $27.79 | 2019-2024 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Binding Site INC. | $25.00 | 2020 | |
| Acadia Pharmaceuticals INC | $24.93 | 2024 | Daybue |
| Corium, LLC | $23.31 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $22.96 | 2024 | Auvelity |
| Collegium Pharmaceutical, INC. | $20.60 | 2025 | Jornay Pm |
| Amarin Pharma, INC. | $18.61 | 2019 | |
| Merck Sharp & Dohme LLC | $17.86 | 2024 | Capvaxive, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $16.78 | 2025 | |
| Inspire Medical Systems, INC. | $16.47 | 2023 | Inspire |
| Amgen INC. | $16.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2019 | |
| Organon LLC | $11.61 | 2025 | Nexplanon |
| Shire North American Group INC | $11.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Blattman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.